Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB-KOLICARE
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
AB-KOLICARE is a probiotic oral drop formulation developed by the Spanish biotechnology company AB-Biotics to treat functional gastrointestinal disorders (FGIDs) in infants, specifically infant colic and functional constipation. It is a combination product containing two patented live bacterial strains: *Bifidobacterium longum* KABP042 (CECT 7894) and *Pediococcus pentosaceus* KABP041 (CECT 8330). The proposed mechanism of action involves modulating the gut microbiota, adhering to and protecting the intestinal epithelium by regulating tight junction proteins, and inhibiting pathogenic bacteria through the production of organic acids and antimicrobials. [7] Clinical trials have shown that AB-KOLICARE can reduce crying and fussing time in infants with colic. [1, 3] A comparative study indicated its superiority over another commonly used probiotic, *Limosilactobacillus reuteri* DSM17938. [5] The product is marketed for use in babies from birth (0+ months). [13]
- Brand names
- AB-KOLICAREAB-KOLICARE D+
- Other names
- Bifidobacterium longum KABP-042 + Pediococcus pentosaceus KABP-041
Beyond the preview
Go deeper on AB-KOLICARE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB-KOLICARE.